Close this search box.

Another Biosimilar to Avastin – Avzivi

……..catching up on FDA Approvals

The FDA recently approved a new infused therapy, Avzivi (bevacizumab-tnjn) from Bio-Thera Solutions, as a biosimilar to AVASTIN (bevacizumab). It did not receive an interchangeable designation.

Avzivi is indicated for the treatment of (refer to prescribing information for full indication):

  • Metastatic colorectal cancer, in combination 
  • Metastatic colorectal cancer, in combination 
  • Non-squamous non-small cell lung cancer, in combination 
  • Recurrent glioblastoma in adults
  • Metastatic renal cell carcinoma in combination 
  • Cervical cancer, in combination 
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination.

CLICK HERE to access prescribing information

Four biosimilar versions of Avastin were previously approved: 

  • Mvasi (bevacizumab-awwb), 
  • Zirabev (bevacizumab-bvzr), 
  • Alymsys (bevacizumab-maly), and 
  • Vegzelma (bevacizumab-adcd).


FDA Approves Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn), a biosimilar referencing Avastin

  • Avzivi (BAT1706) is Bio-Thera Solutions’ second FDA approved product in the United States
  • Avzivi® is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States

CLICK HERE to read the full press release


Read More

CGT Driving New Programs at WAGS

Our last few Reports focused on approvals and developments in the Cell and Gene Therapy (CGT) categories. A recent press release from a major national pharmacy


CGT…… What’s in Your Future?

Today we are pleased to offer a review of an article from which just about anyone working in the specialty pharmacy segment might learn something…. or

Send Us A Message

This website uses cookies to ensure you get the best experience on our website.